장마감
로그인 회원가입
GRFS
GRFS
Grifols SA ADR
7월 27일 4:00 PM ET (한국 7/28 05:00)
$7.76
+0.18 ▲ +2.37%
🌙 7월 27일 5:23 PM ET (한국 7/28 06:23)
$7.75
+0.00 +0.00%

그리폴즈(GRFS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$2.0B
스몰캡
P/E
11.0
저평가 구간
배당수익률
3.15%
52주 위치
19%
저점 +11% · 고점 -30%
애널리스트
보유
C
Fundamental health
vs. Drug Manufacturers - General
수익성 ⓘ
Top 57%
성장 ⓘ
Top 35%
밸류에이션 ⓘ
Top 96%
재무 안정 ⓘ
Top 35%
Index ⓘ -P/E ⓘ 10.98EPS (ttm) ⓘ 0.71Insider Own ⓘ 0.06%Shs Outstand ⓘ 258.2MPerf Week ⓘ 1.97%
Market Cap ⓘ 2.00BForward P/E ⓘ 6.3EPS next Y ⓘ 27.68%Insider Trans ⓘ -Shs Float ⓘ 258.1MPerf Month ⓘ 5.29%
Enterprise Value ⓘ 15.09BPEG ⓘ 0.26EPS next Q ⓘ -Inst Own ⓘ 57.51%Short Float ⓘ 2.46%Perf Quarter ⓘ -3.96%
Income ⓘ 0.48BP/S ⓘ 0.23EPS this Y ⓘ 13.06%Inst Trans ⓘ -3.48%Short Ratio ⓘ 9.34Perf Half Y ⓘ -15.84%
Sales ⓘ 8.62BP/B ⓘ 0.84EPS next 5Y ⓘ 23.86%ROA ⓘ 2.1%Short Interest ⓘ 6.34MPerf YTD ⓘ -17.01%
Book/sh ⓘ 9.24P/C ⓘ 2.48EPS past 3/5Y ⓘ 27.36% -8.34%ROE ⓘ 7.77%52W High ⓘ -30.34% ($11.14)Perf Year ⓘ -23.17%
Cash/sh ⓘ 3.13P/FCF ⓘ 2.32Sales past 3/5Y ⓘ 10.04% 6.88%ROIC ⓘ 2.87%52W Low ⓘ 11.49% ($6.96)Perf 3Y ⓘ -22.4%
Dividend Est. ⓘ $0.24 (3.15%)EV/EBITDA ⓘ 7.86EPS Y/Y TTM ⓘ 129.84%Gross Margin ⓘ 37.04%Volatility(W/M) ⓘ 1.87% 2.24%Perf 5Y ⓘ -48.06%
Dividend TTM ⓘ 0.28EV/Sales ⓘ 1.75Sales Y/Y TTM ⓘ 8.91%Oper. Margin ⓘ 16.46%ATR (14) ⓘ 0.21Perf 10Y ⓘ -55.01%
Dividend Ex-Date ⓘ 2026/7/2Quick Ratio ⓘ 0.85EPS Q/Q ⓘ 35.82%Profit Margin ⓘ 5.58%RSI (14) ⓘ 58.85Recom ⓘ 2.67
Dividend Gr. 3/5Y ⓘ - -8.05%Current Ratio ⓘ 2.47Sales Q/Q ⓘ 5.82%SMA20 ⓘ 5.54% ($7.35)Beta ⓘ 0.66Target Price ⓘ $14.43
Payout ⓘ 34.22%Debt/Eq ⓘ 1.77Earnings ⓘ 2026/5/7SMA50 ⓘ 3.17% ($7.52)Rel Volume ⓘ 0.57Prev Close ⓘ $7.58
Employees ⓘ 25258LT Debt/Eq ⓘ 1.66EPS/Sales Surpr. ⓘ -26.24% -6.1%SMA200 ⓘ -8.33% ($8.47)Avg Volume(3M) ⓘ 0.68MPrice ⓘ $7.76
IPO ⓘ 2011/6/2Option/Short ⓘ Yes/YesTrades ⓘ 2705Volume ⓘ 388,936Change ⓘ 2.37%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Grifols SA ADR (GRFS) Investment Analysis

What kind of company is Grifols SA ADR?

그리폴즈(GRFS) 배당주
Healthcare · Drug Manufacturers - General
Healthcare Stocks

🩸 A global pharmaceutical company that develops and manufactures plasma-derived therapies. It produces plasma protein therapeutics such as immunoglobulins, albumin, and coagulation factors extracted from human plasma, and also operates a worldwide plasma collection network along with a diagnostics business. The company has established itself as a pharmaceutical specialist in plasma medicines with a vertically integrated structure that spans from plasma collection to drug manufacturing.

Learn more about Grifols SA ADR →
Market Cap
$2.0B
Approx. KRW 2.7 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2110
Employees25,258people
IPO2011/06/02
Current Price$7.76 ≈ 10,631원
NASD · Spain

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 7월 2일 (목) 주당 $0.076511
🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS -26.2% 매출 -6.1%
🔔 Earnings release 2026년 2월 26일 (목) · 장 마감 후 EPS -26.2% 매출 -6.1%
🎯 Ex-div 2025년 8월 12일 (화)

Is it profitable?

Profitability weak
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
16.5%
✓ 부진
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General Median 27.0% · Bottom 17%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
5.6%
✓ 부진
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General Median 14.7% · Bottom 22%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
37.0%
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - General Median 69.3% · Bottom tier
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
7.8%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 중형주 Median -17.0% · Top 27%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
2.1%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 중형주 Median -9.3% · Top 29%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
2.9%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 중형주 Median -11.9% · Top 28%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
1.77
✓ High debt
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General Median 0.94
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.47
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - General Median 1.26
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.85
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 1.01
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$14.43
현재가 대비 +86.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
6.30배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.26
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+27.7%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+23.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-26.2%
평균 서프라이즈
2026.05.07
하회
-26.2%
2026.02.26
하회
-26.2%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+13.1%
양호
My positionMid-range
Low range Average High range
배당주 중형주 Median 4.7% · Top 32%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+27.7%
우수
My positionTop 25%
Low range Average High range
배당주 중형주 Median 8.7% · Top 16%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+23.9%
우수
My positionTop 5%
Low range Average High range
배당주 중형주 Median 5.3% · Top tier
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+27.4%
우수
My positionTop 25%
Low range Average High range
배당주 중형주 Median -0.2% · Top 8%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-8.3%
부진
My positionBottom 25%
Low range Average High range
배당주 중형주 Median 4.1% · Bottom 15%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+6.9%
평균
My positionMid-range
Low range Average High range
배당주 중형주 Median 8.2% · Bottom 42%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+5.8%
양호
My positionMid-range
Low range Average High range
배당주 중형주 Median 4.8% · Top 48%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -116%p below the market
GRFS -48.1% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-116.4%p
Significantly behind the market
vs Health Care (XLV)
-72.6%p
Significantly behind the sector average
1-year basis
vs S&P 500
-39.2%p
Significantly behind the market
vs Health Care (XLV)
-42.9%p
Significantly behind the sector average
Current position within 52-week range
Low (-11.5%p) High (-30.3%p)
Current price is 11.5% above the 52-week low and 30.3% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-28.0%
Annualized volatility
35.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $7.76 above the midline ($7.35). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.059 > Signal -0.011 in positive zone + Hist positive (+0.070). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 58.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 80.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
10.98x
✓ Very cheap
My positionTop 5%
Low range Average High range
Drug Manufacturers - General median 20.25x · Top 1% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
6.30x
✓ Very cheap
My positionTop 5%
Low range Average High range
Drug Manufacturers - General median 13.52x · Top 1% — relatively cheap within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
0.84x
✓ Very cheap
My positionTop 5%
Low range Average High range
Drug Manufacturers - General median 6.32x · Top 1% — relatively cheap within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
0.23x
✓ Very cheap
My positionTop 5%
Low range Average High range
Drug Manufacturers - General median 3.17x · Top 1% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
7.86x
✓ Very cheap
My positionTop 25%
Low range Average High range
Drug Manufacturers - General median 11.04x · Top 23% — relatively cheap within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
2.32x
✓ Very cheap
My positionTop 5%
Low range Average High range
Drug Manufacturers - General median 15.70x · Top 1% — relatively cheap within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$14.43 vs. current price +86.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - General

Who owns it?

Ownership flow shows some pressure
Institutional net selling -3.5% · Short interest light 2.5%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-3.5%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 57.5%
Adequate institutional weight
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 0.1%
Low, common among large-caps
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 42.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.5%
Low — limited short-side pressure
Healthcare 중형주 Median 11.3%
Past 90 days Little change
Short interest days to cover
9.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 258.2M주
Float (tradable shares) 258.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding GRFS

ETFs with the highest weightings · 10 total shown
EWP
EWP
iShares MSCI Spain ETF
1.56%
$2.0B
BINV
BINV
Brandes International ETF
1.50%
$504M
BSMC
BSMC
Brandes U.S. Small-Mid Cap Value ETF
1.37%
$171M
VSHY
VSHY
Virtus Newfleet Short Duration High Yield Bond ETF
0.76%
$31M
FHYS
FHYS
Federated Hermes Short Duration High Yield ETF
0.66%
$54M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당주 — 연 3.15% 배당
5년 배당 성장률 -8.05%
Dividend Yield
3.15%
Industry average 1.23%
Dividend Per Share
$0.24
Annualized
Payout Ratio
34%
Share of net income paid as dividends
5-Year Growth
-8.1%
Annualized dividend growth
📅 지급월 8월
📊 총 이력 2013~2025 (17건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.14
2013
$0.30 +120.6%
2014
$0.35 +17.5%
2015
$0.35 -0.7%
2016
$0.38 +7.1%
2017
$0.48 +27.7%
2018
$0.39 -17.7%
2019
$0.20 -49.0%
2020
$0.46 +126.9%
2021
$0.17 -62.1%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 17건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2025-08-12
$0.173
—
1.63%
2021-06-03
$0.456
—
3.92%
2020-10-30
$0.201
—
2.48%
2019-12-02
$0.220
—
1.74%
2019-06-07
$0.174
—
2.11%
2018-11-30
$0.228
—
3.50%
2018-06-01
$0.251
—
2.11%
2017-12-01
$0.212
—
2.55%
2017-05-30
$0.163
—
2.43%
2016-12-05
$0.191
—
3.63%
2016-06-02
$0.159
—
3.04%
2015-12-10
$0.185
—
2.14%
2015-06-08
$0.168
—
2.12%
2014-12-04
$0.157
—
1.73%
2014-06-05
$0.143
—
1.28%
2013-06-05
$0.130
—
1.01%
2013-05-29
$0.006
—
0.05%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 2.6만원
5년 누적 (세후) 11.2만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 -8.05% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
GRFS GRFS This Stock
$2.0B11.0 ▲0.8 ▲7.77% ▲3.15% ▲+2.4%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
그리폴스(GRFS) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
그리폴스(GRFS)는 면역글로불린·알부민 등 혈장 유래 의약품을 제조하는 글로벌 제약 기업으로, 혈장 수집과 면역글로불린 수요, 혈장 단백질 가격과 부채 구조에 매출과 주가가 좌우되며 전망과 관련주에 대한 시장의 관심이 높은 종목입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 그리폴즈(GRFS)?

그리폴즈(GRFS) belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is the market cap of GRFS?

The market cap of GRFS is approximately $2.0B, ranking 2,110 within its sector.

Does GRFS pay dividends?

GRFS has a dividend yield of approximately 3.15%, with an annual dividend of $0.24.

What is the P/E ratio of GRFS?

GRFS has a P/E ratio of approximately 11.0x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for GRFS?

GRFS has recorded a 52-week high of $11.14 and a low of $6.96.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.